Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naeije, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naeije, R.
The Proceedings of the American Thoracic Society 2:20-22 (2005)
© 2005 The American Thoracic Society

Pulmonary Hypertension and Right Heart Failure in Chronic Obstructive Pulmonary Disease

Robert Naeije

Department of Pathophysiology, Erasme Campus, Brussels, Belgium

Correspondence and requests for reprints should be addressed to R. Naeije, M.D., Department of Pathophysiology, Erasme Campus CP 604, Lennik Road, 808, B-1070, Brussels, Belgium. E-mail: rnaeije{at}ulb.ac.be

Pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD). The increase in pulmonary artery pressures is often mild to moderate. However, 5–10% of patients with advanced COPD may suffer from severe pulmonary hypertension and present with a progressively downhill clinical course because of right heart failure added to ventilatory handicap. The prevalence of clinically significant severe pulmonary hypertension in COPD is roughly estimated to be of 1–2/1,000. The cause of pulmonary hypertension in COPD is generally assumed to be hypoxic pulmonary vasoconstriction leading to permanent medial hypertrophy. However, recent pathologic studies point rather at extensive remodeling of all layers of the pulmonary arterial walls. These aspects account for minimal reversibility with supplemental oxygen. There may be a case for pharmacologic treatment of pulmonary hypertension in selected patients with advanced COPD and right heart failure. However, it will be a challenge for randomized controlled trials to overcome the difficulties of the diagnosis of right ventricular failure and the definition of a relevant primary endpoint in pulmonary hypertensive patients with COPD.

Key Words: pulmonary hypertension • chronic obstructive pulmonary disease • right heart failure




This article has been cited by other articles:


Home page
 Eur Respir JHome page
M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension
Eur. Respir. J., July 1, 2008; 32(1): 198 - 209.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
X. Sun and D. D. Ku
Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H801 - H809.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Zakrzewicz, F. M. Kouri, B. Nejman, G. Kwapiszewska, M. Hecker, R. Sandu, E. Dony, W. Seeger, R. T. Schermuly, O. Eickelberg, et al.
The transforming growth factor-{beta}/Smad2,3 signalling axis is impaired in experimental pulmonary hypertension
Eur. Respir. J., June 1, 2007; 29(6): 1094 - 1104.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
K. R. Stenmark, K. A. Fagan, and M. G. Frid
Hypoxia-Induced Pulmonary Vascular Remodeling: Cellular and Molecular Mechanisms
Circ. Res., September 29, 2006; 99(7): 675 - 691.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Thoracic Society.